期刊文献+

AmpC β-内酰胺酶的分子生物学研究进展 被引量:3

暂未订购
导出
摘要 Amp Cβ-内酰胺酶是属 Bush功能分类 群 ,Ambler分子分类 C类的头孢菌素酶 ,主要由染色体介导产生 ,不被克拉维酸抑制 ,能水解第三代头孢菌素、头霉素等广谱 β-内酰胺类抗生素。Amp Cβ-内酰胺酶的表达受amp复合操纵子调控 ,与肽聚糖合成密切相关。amp复合操纵子由 amp C、amp R、amp D和 amp G构成 ,分别编码Amp Cβ-内酰胺酶、转录调节因子 Amp R,N-乙酰葡萄糖胺 - L-丙氨酸酰胺酶 Amp D和膜结合转运蛋白 Amp G。其中 Amp R与 UDP- N-乙酰胞壁酰五肽结合可抑制 amp C转录 ,与 N-乙酰胞壁酰酐三肽结合可激活 amp C转录。调控基因突变及 β-内酰胺类抗生素的诱导作用均可使肽聚糖合成与水解反应失衡 ,导致 N-乙酰胞壁酰酐肽积聚 ,从而使 Amp Cβ-内酰胺酶的产量提高。近年来 ,质粒编码的 Amp Cβ-内酰胺酶逐渐增多 ,源于肠杆菌科细菌 ,与染色体编码的 Amp Cβ-内酰胺酶在分子结构上具不同程度的同源性。Amp Cβ-内酰胺酶的诱导产生及质粒编码的Amp Cβ-内酰胺酶的出现是细菌针对抗生素造成的选择压力而进化的结果 ,临床实践中必须慎用超广谱 β-内酰胺类抗生素。
出处 《国外医药(抗生素分册)》 CAS 2002年第4期165-167,共3页 World Notes on Antibiotics
  • 相关文献

参考文献3

二级参考文献12

  • 1M. D. Kitzis,B. Ferré,A. Coutrot,J. F. Acar,L. Gutmann. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria[J] 1989,European Journal of Clinical Microbiology & Infectious Diseases(9):783~788
  • 2Meyer KS et al. Annals of Internal Medicine . 1993
  • 3Moosdeen F. Clinical Infectious Diseases . 1997
  • 4Bush K et al. Antimicrobial Agents and Chemotherapy . 1995
  • 5Medeiros AA. Clinical Infectious Diseases . 1997
  • 6Jacoby GA et al. Journal of Clinical Microbiology . 1996
  • 7Pitout JDD et al. Antimicrob Agcnts Chemother . 1997
  • 8Jacoby GA et al. Antimicrobial Agents and Chemotherapy . 1991
  • 9Nuesch-Inderbinen MT et al. Antimicrob Agcnts Chemother . 1997
  • 10Rice LB et al. Antimicrobial Agents and Chemotherapy . 1994

共引文献31

同被引文献33

  • 1周强,徐元宏.AmpCβ-内酰胺酶的产生机制及检测方法学进展[J].国外医药(抗生素分册),2004,25(4):176-180. 被引量:9
  • 2王煜,李振华.从大肠埃希菌和肺炎克雷伯菌中检测超广谱β内酰胺酶和AmpC酶(英文)[J].中国现代医学杂志,2004,14(24):6-8. 被引量:11
  • 3Nelson EC, Elisha BG. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coll. Antimicrob Agents Chemother, 1999, 43(4): 957-959.
  • 4Uehara T, Park JT. Role of the murein precursor UDP-N-acetyl-muramyl-L-Ala-gamma-D-Glu-meso-diaminopimelic acid-D-Ala-D-Ala in repression of beta-lactamase induction in cell division mutants. J Bacteriol, 2002, 184(15): 4233-4239.
  • 5Corvec S, Caroff N, Espaze E, et al. -11 Mutation in the ampC promoter increasing resistance to beta-lactams in a clinical Escherichia coil strain. Antimicrob Agents Chemother, 2002, 46(10):3265-3267.
  • 6Mulvey MR, Bryce E, Boyd DA, et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother, 2005, 49(1): 358-365.
  • 7Siu LK, Lu PL, Chen JY, et al. High-level expression of ampC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended spectrum-cephalosporin treatment. Antimicrob Agents Chemother, 2003, 47(7): 2138-2144.
  • 8Caroff N, Espaze E, Berard I, et al. Mutations in the ampC promoter of Escherichia coil isolates resistant to oxyiminocephalosporins without extended spectrum heta-lactamase production. FEMS Microhiol l.ett, 1999, 173(2): 459-465.
  • 9Caroff N, Espaze E, Gautreau D, et al. Analysis of the effects of-42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. J Antimicrob Chemother, 2000.45(6) : 783-788.
  • 10Forward KR, Willey BM, Low DE, et al. Molecular mechanisms of cefoxitin resistance in Escherichia coil from the Toronto area hospitals. Diagn Microhiol Infect Dis, 2001, 41 (1-2) : 57-63.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部